TY  - CONF

T1  - Abstract CT330: Adjusting for confounding effects of treatment crossover in a randomized phase 2 study of dabrafenib plus trametinib inBRAFV600+ metastatic melanoma

JO  - Clinical Trials

PY  - 2014/10/01

AU  - Latimer N

AU  - Amonkar M

AU  - Stapelkamp C

AU  - Sun P

ED  - 

DO  - DOI: 10.1158/1538-7445.am2014-ct330

PB  - American Association for Cancer Research

Y2  - 2025/02/14

ER  -